MDM2 inhibitors not only promote IL-15 production by cancer-associated fibroblasts, macrophages, and B cells but also increase IL-15 production by melanoma cells, with high IL-15 expression positively correlated with mouse viability. The gene discussed is IL15; the disease is melanoma.